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Abstract: We assess the influence of co-occurring psychiatric disorders on retention in 189 
opioid dependent patients in a methadone maintenance treatment (MMT) and determine the 
incidence of psychiatric co-morbidity during an 18-month follow-up period. About 68.5 % 
were  retained  in  the  MMT.  Neither  co-occurring  mental  disorders  (chi-square  =  0.303,  
df = 1, p = 0.622) nor methadone doses [85 (88.9) vs. 79.2 (85) mg/day, p = 0.672] were 
related to retention. In the follow-up period 19 new diagnoses were made, mainly major 
depression  and  antisocial  and  borderline  personality  disorders.  Co-occurring  psychiatric 
disorders should be assessed during MMT follow-up. 
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1. Introduction 
 
In  the  management  of  heroin  dependent  subjects  methadone  maintenance  treatment  (MMT) 
programs are effective in reducing heroin use, crime related to drug use, HIV risk behaviors, overdose 
mortality [1-3] and improving quality of life [4,5]. Effectiveness is related to the effect of methadone 
on retaining patients  in the program. Research  into the  factors related to retention  in MMT  is  an 
important issue in order to improve the effectiveness of MMT.  
Previous  studies  suggest  that  the  patient  must  stay  for  at  least  one  year  in  the  MMT  for  the 
treatment to be effective [6,7] although longer treatment is recommended. In different studies, the  
1-year retention rate ranges between 25% to 82% [6,8-13]. Factors associated with retention rate are 
methadone dosage [2,14], differences between treatment settings [15], severity of drug use at the time 
of enrolment in the program [16] and age at time of MMT entrance [17]. The influence of co-occurring 
mental  disorders  other  than  substance  abuse  has  also  been  studied,  although  results  remain 
controversial [11,13,15,18]. This could be mainly related to the difficulties in diagnosing co-occurring 
disorders in substance users [19,20] and to the fact that in previous studies the patients were only 
assessed  at  the  time  of  admission  into  MMT  and  therefore  the  role  of  new  non-substance  use 
psychiatric diagnosis during the follow-up period was not considered. 
A prospective follow-up study of opioid dependent patients included in the MMT [21] was carried 
out with the following objectives: (1) to assess the influence of co-occurring disorders on retention in 
the MMT program and (2) to determine the incidence of co-occurring disorders during an 18-month 
follow-up. 
 
2. Methods 
 
2.1. Sample 
 
The study participants were 189 opioid dependent patients (77% male, mean age 34 ±  7.5 years) 
consecutively admitted to a MMT in Barcelona, Spain, and followed up to 18 months.  
 
2.2. Procedure 
 
In the baseline visit, after full explanation of the purposes of the study, written informed consent 
was  obtained  and  patients  were  assessed  with  the  PRISM-IV  and  a  close-ended  questionnaire  
(see other variables). At follow-up (18 months) patients were reassessed with the same measures. The 
study protocol was approved by the institutional review board. 
 
2.3. Methadone Maintenance Treatment 
 
The  MMT  provided  at  the  Drug  Abuse  Out-patient  Centre  (CAS-BARCELONETA)  is  a  
low-threshold MMT, that is to say such program is not abstinence oriented. The only requirement for 
inclusion in the program is a definitive diagnosis of opioid dependence according to DSM-IV criteria. 
Forced discharge only occurs for aggressive behavior and drug trafficking in the centre. There is a high Int. J. Environ. Res. Public Health 2009, 6                 
 
 
2824 
dose policy (no upper limit) and no restriction on long-term treatment (no time limit). The induction 
period  on  MMT  lasts  about  1–2  months  until  the  stable  maintenance  doses  is  achieved.  Urine 
toxicology screens are carried out randomly once a week under supervision. Methadone is dispensed to 
patients daily on the form of syrup with orange juice and has to be ingested in the presence of a nurse. 
Take-home  methadone doses are provided when weekly urine screening tests are repeatedly clean  
(at least for a period of one month). Take-home privileges are revoked in response to positive urine 
tests results, and patients are referred to the clinicians to assess a possible increase in methadone doses. 
In addition to methadone and urine drug screen, individual counseling is the major therapeutic vehicle 
and frequency varies depending upon the stage of treatment and patient needs. Counseling focused on 
encouraging  reduced  drug  use  and  helping  patients  to  cope  with  problems  (either  through  direct 
counseling  or  referral  to  other  services)  that  made  them  more  vulnerable  to  continued  drug  use  
is provided. 
 
2.4. Current Co-Occurring Diagnoses 
 
Diagnoses of current substance use disorder (SUD) and co-occurring mental disorders, were carried 
out according to DSM-IV criteria and using the Spanish version of the Psychiatric Research Interview 
for  Substance  and  Mental  Disorders  (PRISM-IV)  [22],  administered  by  two  trained  psychologist 
researchers  with  clinical  experience  with  patients  with  substance  abuse  or  mental  disorders.  The 
PRISM-IV has shown a good test-retest reliability [23] and validity [22] in substance abusers. 
 
Figure 1. Situation of the 189 opioid dependent patients admitted to a MMT at 18 months 
follow-up. 
 
* Co-occurring disorders: co-occurring substance use [abuse or dependence] and mental disorders. Int. J. Environ. Res. Public Health 2009, 6                 
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2.5. Other Variables 
 
Baseline patient’s sociodemographic characteristics (including employment and legal status), and 
drug use and sexual risk behaviors, substance use variables, and infection by HIV and hepatitis C virus 
were collected with a close-ended questionnaire [21]. At follow-up, the questionnaire included data on 
MMT provided (methadone dose received at 18 months). In the patients not retained in the program, 
data on the last methadone dose administered before interruption of MMT was used.  
 
2.6. Statistical Analysis 
 
All statistical analyses were carried out with the SPSS statistical software package [SPSS V14; 
Chicago, IL, USA]. Retention in the MMT was defined as remaining in the same MMT program, and 
after  stable  doses  of  methadone  was  reached.  The  presence  of  co-occurring  mental  disorders  at 
baseline  between  retained  and  non-retained  patients  was  compared  with  Pearson's  chi-square  test. 
Fisher's exact test was used when one or more cells of the contingency tables had expected counts of 
less than five. 
To determine which variables were associated with MMT retention, we compared retained versus 
non-retained patients in the following baseline variables: sociodemographic (sex, age, education level, 
employment, legal  status); psychopathological (co-occurring  mental disorders [yes/no]); use of the 
following substances during the last month: alcohol, sedatives, cocaine, cannabis, opiates other than 
heroine; SUD diagnoses (yes/no) of the following substances: alcohol, sedatives, cocaine, cannabis, 
opiates other than  heroine; VIH/Hepatitis  C risk-related variables:  i.v. route use, sharing  injection 
material, sexual risk behavior (yes/no for always using condoms); presence or absence of HIV-Ab 
and/or HCV-Ab; and methadone dose. Comparisons were made by means of Pearson's chi-square test 
or  Fisher's
  exact  test  (for  categorical  variables)  and  Student´ s  t-test  (for  continuous  variables).  A 
logistic regression analysis with retention as the dependent variable and those of the former variables 
that showed a p-value of less than 0.25 in the univariate analyses: sex, age, educational level, and 
current diagnosis of cocaine and opiates other than heroin dependence as independent variables was 
done. The goodness-of-fit of the model was assessed by the Hosmer–Lemeshow test. 
To assess the incidence of co-occurring disorders during the follow-up, the cumulative incidence 
(ratio of incident cases divided by those subjects without co-occurring disorders at baseline) and the 
incidence  rate  (ratio  of  new  diagnoses  divided  by  total  time  of  follow-up)  of  retained  cases  
were calculated. 
Exact  95  %  confidence  intervals  for  the  incidence  rate  based  on  the  Poisson  distribution  
were calculated. 
 
3. Results 
 
Table 1 shows a summary of the baseline characteristics of the sample differentiating among those 
128 (67.7%) cases with only a current SUD diagnosis and 61 (32.3%) with a current co-occuring 
mental  disorders.  Anxiety  disorders  were  the  most  frequent  Axis-I  diagnoses,  followed  by  mood Int. J. Environ. Res. Public Health 2009, 6                 
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disorders, and psychotic disorders. More than 20% of the sample fulfilled the criteria for antisocial or 
borderline personality disorder.  
 
Table 1. Differences between patients with/without co-occurring disorders at baseline. 
 
Variable 
Co-occurring 
disorders 
N = 61 (%) 
Only SUD 
N = 128 (%) 
 

2 or t 
 
df 
 
p 
Women  20 (32.8)  24 (18.8)  
2 = 4.557  1  0.043 
Age, years, mean (SD)  33.34 (8.8)  34.1(6.8)  t = –0.637  187  0.525 
Marital status 
 Single 
 Currently married 
 Separated/divorced 
 
42 (68.9) 
12 (19.7) 
7 (11.5) 
 
60 (46.9) 
45 (35.2) 
23 (18) 
 
 

2 = 8.079 
 
 
2 
 
 
0.018 
Education level 
 Primary School 
 Secondary School 
 University 
 
29 (47.5) 
20 (32.8) 
12 (19.7) 
 
47 (36.7) 
50 (39.1) 
31 (24.2) 
 
 

2 = 2.018 
 
 
2 
 
 
0.365 
 Any month employed last six months  26 (42.6)  87 (68)  
2 = 11.039  1  0.001 
Legal status 
 Any detention last six months 
 Any imprisonment last 6 months 
 
20 (32.8) 
7 (11.5) 
 
24 (18.8) 
11 (8.6) 
 

2 = 4.557 

2 = 0.398 
 
1 
1 
 
0.043 
0.598 
Serological status 
 HIV—Ab positive 
 HCV—Ab positive 
 
18 (29.5) 
39 (63.9) 
 
27 (21.8) 
58 (48.7) 
 

2 = 1.329 

2 = 3.747 
 
1 
1 
 
0.276 
0.059 
HIV current risk behaviors last six 
months 
 Any i.v. drug use 
 Any sexual risk behavior  
 
38 (62.3) 
30 (49.2) 
 
57 (44.5) 
73 (57) 
 

2 = 5.215 

2 = 1.027 
 
1 
1 
 
0.029 
0.350 
Drug use last 30 days 
 Alcohol 
 Cocaine 
 Sedatives 
 Other opiates 
 Cannabis 
 
5 (8.2) 
10 (16.4) 
15 (24.6) 
9 (14.8) 
18 (29.5) 
 
23 (18) 
15 (11.7) 
16 (12.5) 
21 (16.4) 
35 (27.3) 
 

2 = 3.127 

2 = 2.402 

2 = 4.423 

2 = 0.084 

2 = 0.586 
 
2 
2 
2 
2 
2 
 
0.209 
0.301 
0.110 
0.834 
0.746 
Cocaine route use 
 Snorted/Smoked 
 Injected 
 
13 (38.2) 
21 (61.8) 
 
27 (50) 
27 (50) 
 

2 = 1.165 
 
1 
 
0.380 
Heroine route use 
 Smoked/Inhaled 
 Snorted 
 Injected 
 
12 (18.7) 
11 (18) 
38 (62.3) 
 
37 (28.9) 
33 (25.8) 
58 (45.3) 
 
 

2 = 4.770 
 
 
1 
 
 
0.092 
 
Abuse or dependence diagnoses 
 Alcohol 
 Other opiates 
 Cocaine 
 Sedatives 
 Cannabis 
 Stimulants 
 
6 (9.8) 
4 (6.6) 
25 (41) 
11 (18) 
17 (27.9) 
2 (3.3) 
 
12 (9.4) 
9 (7) 
43 (33.6) 
18 (14.1) 
20 (15.6) 
2 (1.6) 
 

2 = 0.010 

2 = 0.014 

2 = 0.979 

2 = 0.501 

2 = 3.934 

2 = 0.587 
 
1 
1 
1 
1 
1 
1 
 
1 
1 
0.335 
0.520 
0.053 
0.596 Int. J. Environ. Res. Public Health 2009, 6                 
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Table 1. Cont. 
Non-SUD co-occurring diagnoses 
 Only Axis I 
 Only Axis II 
 Both Axis I + II 
 
32 (52.5) 
22 (36.1) 
7 (11.5) 
 
- 
- 
- 
     
 Major depression 
 Induced depression 
 Schizophrenia 
 Panic w/without agoraphobia 
 Social phobia 
 Simple phobia 
 Post traumatic stress 
 Obsessive compulsive 
 Bulimia 
9 (14.8) 
5 (8.2) 
5 (8.2) 
12 (19.7) 
10 (16.4) 
8 (13.1) 
- 
4 (6.6) 
1 (1.6) 
       
Antisocial Personality Disorder 
Borderline Personality Disorder 
16 (26.2) 
13 (21.3) 
       
Co-occurring diagnoses: co-occurring substance use [abuse or dependence] and mental disorders; Only 
SUD: Only substance use disorders. 
 
The situation of patients during the 18-month follow-up period is shown in Figure 1. Sixty-three of 
the  189  patients  dropped out the  study  because  of  death,  imprisonment  or  MMT  discontinuation. 
Therefore,  a  total  of  126  patients  were  followed,  with  a  retention  rate  of  68.5%.  Some  baseline 
differences between the 126 patients who continued in the MMT and the 63 patients who dropped out 
were found. Subjects that dropped out used more cocaine, (57.1%  vs. 38.1%; chi square = 7.510,  
df = 2, p = 0.023), reported more i.v. route (65.1% vs. 42.9%; chi square = 8.297, dfl = 1, p = 0.005) 
and less sexual risk behaviors (36.5% vs. 63.5%; chi square = 12.333, dfl = 1, p = 0.001) during last 30 
days  before  starting  in  the  MMT.  Furthermore,  subjects  that  dropped  out  had  more  past  
(68.3%  vs.  51.6%;  chi  square  =  4.764,  df  =  1,  p  =  0.030)  and  current  (44.4%  vs.  27%;  
chi square = 5.809, df = 1, p = 0.021) cocaine dependence diagnoses than subjects who continued in 
the MMT.  
Twenty-nine  patients  were  not  available  for  reassessment  at  follow-up,  even  if  still  in  MMT. 
Baseline differences were found respect to those 97 patients retained in MMT and reassessed at follow 
up.  The  29  who  did  not  accepted  to  be  reassessed  used  more  the  i.v.  route  (65.5%  vs.  36.1%;  
chi square = 7.898, df = 1, p = 0.006) and higher alcohol (17.2% vs. 13.4%; chi square = 7.236, df = 2, 
p = 0.027) and cocaine (58.6% vs. 19.6%; chi square = 17.731 df = 2, p < 0.001) in the 30 days before 
entering  MMT.  Furthermore,  the  29  patients  had  more  antisocial  personality  disorder  diagnoses 
(17.2% vs. 4.1%; chi square = 5.792, df = 1, p < 0.030) (data not shown). 
Of the 61 patients with co-occurring mental disorders at baseline, 39 (63.9 %) were retained in the 
MMT programme and 22 (36.1 %) were lost to follow-up, whereas from the 128 without co-occurring 
mental  disorders,  87  (68%)  patients  were  retained  (chi-square  =  0.303,  df  =  1,  p  =  0.622).  No 
difference  in  baseline  characteristics  were  observed  between  the  patients  retained  in  MMT  and 
available for the reassessment at time of follow-up (n = 97) and those retained but not available for the 
reassessment (n = 29). The difference between methadone dosage of those patients retained in the 
MMT  and  last  dose  administered  in  those  who  dropped  out  was  not  statistically  significant  
[85.5 (88.9) vs. 79.2 (85) mg/day, p = 0.672]. None of the variables included in the multivariate model Int. J. Environ. Res. Public Health 2009, 6                 
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were significant predictors of treatment retention, although being male (OR: 2.59, 95% CI: 0.98–6.84;  
p  =  0.055)  and  lower  educational  level  (OR:  2.65,  96%  CI:  0.98–7.13;  p  =  0.054)  were  nearly 
significant predictors of non-retention. The p-value of the Hosmer-Lemeshow tests was 0.47 indicating 
that the model fit was satisfactory. 
A  total  of  107  patients  were  available  for  the  assessment  of  co-occurring  mental  disorders  at  
follow-up. Co-occurring disorders were established in 29 subjects. When patients with (n = 29) and 
without (n = 78) co-occurring disorders were compared, those with co-occurring disorders had worked 
fewer months before admission in the MMT (41.4% vs. 69.2%, p = 0.013) and before reassessment at 
follow-up (24.1% vs. 50%, p = 0.027), showed higher percentage of current alcohol abuse diagnoses 
(13.8%  vs.  1.3%,  p  =  0.019)  and  had  received  more  psychiatric  treatment  (44.8%  vs.  19.2%,  
p = 0.012). 
In 10 of the 107 patients, at least one new co-occurring disorder was diagnosed, with a total of 19 
diagnoses. Sixty percent of these 10 patients were men, with a mean age of 31.60 (5.73) years. The 
cumulative incidence of co-occurring disorders was 13% (95% CI 6.4% to 22.5%). The cumulative 
incidence in the 97 patients retained in the MMT program and reassessed was 11.43 % (95% CI 5.07% 
to 21.28%) compared with 28.6% (95% CI 3.7% to 71%) in 10 patients reassessed but not retained in 
the MMT program. 
Of the 19 new diagnoses, 16 were made in the 97 patients retained in MMT and reassessed, and 3 in 
the subsample of 10 patients not retained but reassessed. The incidence rate of co-occurring disorders 
at follow-up was 0.11 diagnoses per year (95% CI 0.06 to 0.18) in patients retained in MMT and 0.20 
(95% CI 0.04 to 0.58) in those not retained. Nine new Axis I diagnoses were done: major depression 
(five diagnoses), anxiety disorders (one panic disorder and one specific phobia) and psychotic disorder 
(one induced and one primary). Regarding Axis II disorders, 10 new diagnoses had been made of 
personality  disorders  (five  antisocial  personality  disorder  [APD]  and  five  borderline  personality 
disorder [BPD]); see Table 2 for more details. 
 
Table  2.  Co-occurring  disorders  incidence  in  a  cohort  of  107  patients  reassessed  at  
18 months. 
  Co-occurring disorders 
Disorders at baseline  Baseline  Follow-up 
    Axis I  Axis II  Axis I & II 
Only SUD   77  1 Induced 
Psychosis
a 
1 Simple Phobia 
1 Schizophrenia 
1 APD & BPD
a,b 
1 APD 
2 BPD 
 
Non SUD co-occurring diagnoses  30       
Axis I  19       
 Major Depression  7 
  1 BPD 
1 Induced 
Depression & 
BPD
b 
 Induced Depression  1       
 Schizophrenia  2       
 Induced Psychosis  -       
 Panic w/without Agoraphobia  9  3 Major Depression     
 Social Phobia  6    2 APD   Int. J. Environ. Res. Public Health 2009, 6                 
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Table 2. Cont. 
 Simple Phobia  4       
 Obsessive Compulsive  3    1 APD   
Axis II  8       
 Antisocial Personality  5       
 Borderline Personality  6       
Axis I & II  3       
 Social Phobia, Induced Depression 
& BPD 
1  1 Major 
Depression     
 Panic with/without Agoraphobia & 
BPD 
1  1 Major 
Depression     
 Panic with/without Agoraphobia & 
APD 
1       
a Patients from the subsample of 10 patients not retained but assessed; 
b Both diagnoses in single patient; 
APD: Antisocial personality disorder; BPD: Borderline personality disorder. 
 
4. Discussion  
 
In  this  study,  the  overall  cumulative  incidence  of  co-occurring  disorders  in  methadone-treated 
opioid dependent patients followed-up for 18 months was 13%. Major depression and antisocial and 
borderline personality disorders were the most common new diagnoses. The cumulative incidence, 
although not statistically significant, was lower in patients retained in MMT than those not retained. 
Moreover, co-occurring disorders at the time of inclusion in the MMT was not related to retention  
in treatment.  
Major depression has been the main incident Axis I diagnoses. Interestingly, all those patients had 
been diagnosed with an anxiety disorder at baseline. Our results are similar to those obtained by others 
at  12  months  follow-up  after  discharge  of  inpatient  detoxification  treatment  using  similar  
methodology [20], but differ  from those of Grant  et al. [24], suggesting that anxiety disorders at 
baseline more often predicted incidence of anxiety disorders rather than mood disorders in the general 
population.  The  establishment  of  new  personality  disorders  was  indeed  quite  surprising,  since  a 
personality disorder implies a pattern of behaviors developing through one’s adult life, beginning in 
the early adulthood. Such result could be explained by the fact that at baseline patients were diagnosed 
just at admission of MMT and it was more difficult to differentiate personality than substance related 
symptoms. In agreement with other authors  [13,25], we consider that the diagnoses of personality 
disorders should be done once the patients have become clinically stabilized. 
Although in the univariate analysis, cocaine use as IV use at entrance, was a predictor of drop-out 
of  treatment  in  agreement  with  previous  studies[26],  in  the  multivariate  regression  analysis,  no 
significant relationship was proven between these variables and the retention in MMT. Nor did we find 
other significant predictor of retention in MMT, although statistical significance was almost reached 
for two variables (gender and education level). It seems that patients with a lower educational level 
might need some specific treatment approaches, such as mapping-enhanced counseling to improve 
treatment outcomes. Previous studies [27,28] found controversial results regarding education level and 
MMT retention. We did not observe a relationship between methadone dose and retention in treatment, 
probably because mean dose of methadone administered (near 80 mg/day in both groups) was in the Int. J. Environ. Res. Public Health 2009, 6                 
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recommended range [14]. Psychiatric comorbidity did not show any influence on patient’s retention in 
MMT, as previously described by other authors[11,13,18]. 
Some study limitations should be mentioned. Firstly, the lack of the assessment of psychosocial 
interventions received during the treatment, and secondly, the fact that co-occurring mental disorders 
were only evaluated in a small percentage of subjects not retained in the MMT.  
In  summary,  the  present  study  shows  a  relatively  high  cumulative  incidence  of  co-occurring 
diagnoses  (mainly  major  depression)  among  opioid  dependent  patients  available  at  follow-up. 
Furthermore, the unexpected rate of new personality disorder diagnoses established in MMT retained 
patients enhances the relevance of careful detection of co-occurring mental disorders not only at the 
time admission to the treatment, but also throughout the whole program. 
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